Últimas noticias sobre Susquehanna Community (OTC:SQCF) Bolsa

Susquehanna Community

Susquehanna Community Financial Inc is a United States-based bank holding company. Through its subsidiary bank, it offers general banking services to individuals and corporates. The bank provides services like mortgage services, online banking and bill pay, telephone banking, savings, checking, direct deposits, debit cards, credit cards and other services.

SUSQUEHANNA CMMTY FNCL by Susquehanna Community Financial, Inc.

Susquehanna Community Financial Inc

ZyVersa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>, "ZyVersa"))), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, announces that it has entered into a share purchase agreement (SPA) with Williamsburg Venture Holdings (WVH), an institutional investor. We anticipate that this partnership will provide a flexible source of funding, enabling the company to progress clinical development of Cholesterol Efflux Mediator&#x2122;&nbsp;VAR 200 to treat chronic kidney diseases. The global drug market for kidney diseases was $18 Billion in 2024, with $30 Billion projected by 2034 (Precedence Research).
The SPA allows ZyVersa to be judicious and plan for the timing and amount of any equity sales as we advance clinical development of VAR 200 to achieve key milestones. We aim to use the SPA in a manner that will minimize dilution while creating and sustaining shareholder value.
Under the terms of the agreement, ZyVersa has the right to sell, and WVH has the obligation to purchase up to $10 million worth of common stock over a 24-month period at prices that are a discount to the market price after each sale to WVH. ZyVersa, at its sole discretion, controls the timing and amount of all sales of common stock. There are no warrants, derivatives, or other share classes associated with the SPA. In connection with the execution of the SPA, ZyVersa will issue 2.5% of commitment shares to WVH over the term of the deal, based on the percentage of the $10 million of common stock that has been purchased by WVH.

News

ZVSA

ZyVersa Therapeutics Enters Into SPA For Up To $10M In Partnership With Williamsburg Venture Holdings To Fund Clinical Development Of Cholesterol Efflux Mediator VAR 200

Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) saw its stock move higher during Wednesday&#8217;s premarket session following an index inclusion that marks a new <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46089974/pony-ai-added-to-nasdaq-golden-dragon-china-index-shares-surge-16-7" rel="noreferrer noopener">milestone for the autonomous driving firm</a>.
The company was officially added to the Nasdaq Golden Dragon China Index on June 23, making it the only pure-play autonomous vehicle company represented in the benchmark.
Pony.ai&#8217;s inclusion highlights its growing relevance among U.S.-listed Chinese companies and places it alongside major tech names like Alibaba Group Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>).
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/45817700/pony-ai-begins-testing-futuristic-robotaxis-in-china-mass-rollout-could-be-next" rel="noreferrer noopener">Pony.ai Begins Testing Futuristic Robotaxis In China, Mass Rollout Could Be Next</a>
The index, which now includes 73 firms, is tracked globally as a proxy for Chinese corporate performance on American exchanges.
Founded in 2016, Pony.ai focuses on autonomous vehicle technologies and currently operates a fleet of around 300 robotaxis across four major cities in China: Beijing, Shanghai, Guangzhou, and Shenzhen.
The firm&#8217;s vehicles are equipped to navigate varied traffic and weather conditions, supporting real-world commercial applications.
In April, the company launched its seventh-generation autonomous driving system, the first to fully integrate automotive-grade hardware. This upgrade reduced manufacturing costs by roughly 70%.
Pony.ai plans to expand its fleet to 1,000 vehicles by the end of 2025.
&#8220;Being included in the Nasdaq Golden Dragon China Index marks a milestone for Pony.ai as a newly listed company,&#8221; said Leo Wang, CFO of the company.
He added that broader visibility will support efforts to commercialize autonomous mobility solutions worldwide.
Shares of Pony.ai jumped 16.7% on June 24 following the announcement. The Nasdaq Golden Dragon China Index itself rose 3.3% on the same day, its strongest daily performance in over a month.
Investors tracking Chinese innovation can also consider Xpeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>), a peer in the EV space.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, PONY stock has gained over 10% in the past year.
Price Action: PONY shares are trading higher by 7.84% to $14.30 premarket at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45966176/after-nvidia-pauses-china-outlook-top-chinese-automakers-race-to-ditch-foreign-chips-aim-for-100-domestic-supply-by-2027-report">After Nvidia Pauses China Outlook, Top Chinese Automakers Race To Ditch Foreign Chips, Aim For 100% Domestic Supply By 2027: Report</a></li>
</ul>

Asia

Equities

Markets

Movers

Tech

General

BABA

PONY

XPEV

Pony.ai Rides High After Nasdaq Golden Dragon China Index Inclusion

H.B. Fuller Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) will release earnings results for the second quarter, after the <a href="https://www.benzinga.com/quote/FUL/earnings">closing bell on Wednesday, June 25.</a>
Analysts expect the Saint Paul, Minnesota-based company to report quarterly earnings at $1.08 per share, on revenue of $899.95 million, according to data from Benzinga Pro.
On April 15, H.B. Fuller raised its quarterly dividend by 5.6%.
H.B. Fuller shares gained 1.3% to close at $56.88 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/ful/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Baird analyst Ghansham Panjabi upgraded the stock from Neutral to Outperform with a price target of $60 on April 17, 2025. This analyst has an accuracy rate of 78%.</li>
<li>JP Morgan analyst Jeffrey Zekauskas maintained an Underweight rating and cut the price target from $60 to $50 on March 28, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Seaport Global analyst Michael Harrison downgraded the stock from Buy to Neutral on March 5, 2025. This analyst has an accuracy rate of 64%.</li>
<li>Deutsche Bank analyst David Begleiter maintained a Buy rating and cut the price target from $75 to $72 on Jan. 22, 2025. This analyst has an accuracy rate of 72%.</li>
</ul>
Considering buying FUL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/ful/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="563" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25034034/image-369-1024x563.png" alt="" class="wp-image-961065" style="width:619px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25034034/image-369-1024x563.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25034034/image-369-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25034034/image-369-768x422.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25034034/image-369.png 1152w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46072226/top-3-real-estate-stocks-you-may-want-to-dump-in-june">Top 3 Real Estate Stocks You May Want To Dump In June</a> </li>
</ul>
Photo via Shutterstock

Earnings

Price Target

Analyst Ratings

Trading Ideas

Top Wall Street Forecasters Revamp H.B. Fuller Expectations Ahead Of Q2 Earnings

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the communication services sector.
<h3 class="wp-block-heading">Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 3.75%</li>
<li>Rosenblatt analyst Bbarton Crockett maintained a Neutral rating with a price target of $36 on April 28, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Morgan Stanley analyst Benjamin Swinburne maintained an Equal-Weight rating and slashed the price target from $38 to $37 on April 25, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Recent News: Comcast will host a conference call with the financial community to discuss financial results for the second quarter on Thursday, July 31.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0625">CMCSA news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0625"><img loading="lazy" decoding="async" width="903" height="578" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25075049/image-379.png" alt="" class="wp-image-961480" style="width:611px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25075049/image-379.png 903w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25075049/image-379-300x192.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25075049/image-379-768x492.png 768w" sizes="(max-width: 903px) 100vw, 903px" /></a></figure>
<h3 class="wp-block-heading">Omnicom Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMC#NYSE">OMC</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 3.86%</li>
<li>JP Morgan analyst David Karnovsky maintained an Overweight rating and lowered the price target from $116 to $104 on April 16, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Wells Fargo analyst Steven Cahall maintained an Equal-Weight rating and slashed the price target from $99 to $84 on April 16, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: On April 15, Omnicom Group reported worse-than-expected first-quarter revenue results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0625">OMC news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0625"><img loading="lazy" decoding="async" width="890" height="717" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25075116/image-380.png" alt="" class="wp-image-961482" style="width:569px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25075116/image-380.png 890w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25075116/image-380-300x242.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25075116/image-380-768x619.png 768w" sizes="(max-width: 890px) 100vw, 890px" /></a></figure>
<h3 class="wp-block-heading">AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 3.93%</li>
<li>UBS analyst John Hodulik maintained a Buy rating and raised the price target from $30 to $31 on June 18, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Tigress Financial analyst Ivan Feinseth maintained a Buy rating and raised the price target from $32 to $34 on April 29, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Recent News: AT&amp;T will release second-quarter earnings on July 23.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0625">latest T news</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0625"><img loading="lazy" decoding="async" width="922" height="822" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25075149/image-381.png" alt="" class="wp-image-961483" style="width:590px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25075149/image-381.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25075149/image-381-300x267.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25075149/image-381-768x685.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46072226/top-3-real-estate-stocks-you-may-want-to-dump-in-june">Top 3 Real Estate Stocks You May Want To Dump In June</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Dividends

Pre-Market Outlook

CMCSA

Wall Street's Most Accurate Analysts Spotlight On 3 Tech And Telecom Stocks With Over 3% Dividend Yields

Delek Logistics Partners, LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKL#NYSE">DKL</a>) ("Delek Logistics") announced today that it, along with Delek Logistics Finance Corp., a subsidiary of Delek Logistics, intends to offer $500 million in aggregate principal amount of senior notes due 2033 (the "Notes") in a private placement to eligible purchasers, subject to market conditions.
Delek Logistics intends to use the net proceeds from the offering to repay a portion of the outstanding borrowings under its revolving credit facility.

Delek Logistics Partners Subsidiary Intends To Offer $500M In Aggregate Principal Amount Of Senior Notes Due 2033 In Private Placement

Benchmark analyst Cody Acree maintains Indie Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) with a Buy and raises the price target from $6 to $8.

INDI

Benchmark Maintains Buy on Indie Semiconductor, Raises Price Target to $8

BKNG moves up over 95 points after alert
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/24201503/Screenshot-2025-06-24-at-4.14.01%E2%80%AFPM-994x1024.png" alt="" class="wp-image-14850" /></figure>
Booking Holdings Inc. (Nasdaq: BKNG) experienced a Power Inflow today, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:42 AM on June 24th, a significant trading signal occurred for Booking Holdings Inc. (BKNG) as it demonstrated a Power Inflow at a price of $5421.63. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Booking's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Booking's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for BKNG, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_June2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_June2025</a>, which are responsible for parts of the data within this article.
After Market Close UPDATE:
The price at the time of the Power Inflow was $5421.63. The returns on the High price ($5516.93) and Close price ($5482.33) after the Power Inflow are respectively 1.8% and 1.1%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Results are not indicative of Future results.

Technicals

Opinion

Signals

Booking Shares Rise 1.8% After Key Trading Signal

CMND-100 has the potential to provide an innovative and advanced treatment option for hundreds of millions of people around the world afflicted with Alcohol Use Disorder
Vancouver, Canada, June 25, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, recently announced the enrollment of the first patient in its Phase I/IIa clinical trial for CMND-100, the Company's proprietary MEAI-based oral drug candidate for the treatment of Alcohol Use Disorder (AUD).
The first patient was enrolled at Yale School of Medicine's Department of Psychiatry, marking a significant milestone in the trial.
The trial is evaluating the safety, tolerability, and pharmacokinetic profile of CMND-100, with preliminary efficacy assessments to explore its potential in reducing alcohol cravings and consumption. This first-in-human study represents a pivotal step toward developing a groundbreaking treatment for individuals struggling with AUD.
Eligible subjects for the clinical trial, among others, are individuals aged 18 to 60. Participants may be either non-treatment-seeking individuals who report heavy binge drinking (defined as at least five standard drinks in a day for men or at least four for women) on at least five days in the past month prior to screening, or treatment-seeking individuals diagnosed with Alcohol Use Disorder (AUD) per DSM-5 criteria, who report at least four binge drinking days in the month prior to screening. All subjects must express a desire to reduce or stop drinking.
The Phase I/IIa clinical trial is being conducted at multiple sites, including Yale School of Medicine and Johns Hopkins University School of Medicine, while the Company is valuating additional clinical sites. Clearmind remains committed to advancing its robust intellectual property portfolio and pioneering psychedelic-derived therapeutics to address global health challenges.

CMND

Clearmind Medicine Enrolls First Patient In Phase I/Iia Clinical Trial For CMND-100, Proprietary MEAI-Based Oral Drug Candidate For Treatment Of AUD

Biotech

Health Care

PHIO

Phio Pharmaceuticals Announced That The Safety Monitoring Committee Recommended Dose Escalation In Its Phase 1b Clinical Trial Of Intratumoral PH-762 In The Treatment Of Stages 1, 2, And 4 Cutaneous Squamous Cell Carcinoma, Stage 4 Melanoma, And Stage 4 Merkel Cell Carcinoma

BCRX

FDA Extends PDUFA Date To December 12, 2025 For BioCryst ORLADEYO NDA In Pediatric HAE After Major Amendment Submission

Politics

Global

Beijing Asks Rare-Earth Firms For Information About Their Experts;  Aims To Keep Tabs On Experts, Prevent Trade-Secret Leaks

DAKT

Daktronics Says Business And Digital Transformation On Track; Reconfirms Three Year Forward Objectives Of 7%-10% Sales Growth, 10%-12% Operating Margin, 17%-20% ROIC

Daktronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAKT#NASDAQ">DAKT</a>) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.15 by 17.65 percent. This is a 33.33 percent decrease over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $172.55 million which missed the analyst consensus estimate of $193.96 million by 11.04 percent. This is a 20.07 percent decrease over sales of $215.88 million the same period last year.

Earnings Beats

Earnings Misses

Daktronics Q4 Adj. EPS $0.18 Beats $0.15 Estimate, Sales $172.55M Miss $193.96M Estimate

Crypto markets are holding steady, boosted by growing optimism over a potential Federal Reserve rate cut, <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46068856/peter-schiff-slams-texas-for-authorizing-bitcoin-reserve-another-example-of-why-the-founding-fathers-distrusted-democracy">Arizona's new Bitcoin reserve law</a>, and continued institutional accumulation. 
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price</td>
</tr>
<tr>
<td>Bitcoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$107,127.27</td>
</tr>
<tr>
<td>Ethereum</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,426.90</td>
</tr>
<tr>
<td>Solana</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$145.86</td>
</tr>
<tr>
<td>XRP</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.19</td>
</tr>
<tr>
<td>Dogecoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1653</td>
</tr>
<tr>
<td>Shiba Inu</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001162</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul class="wp-block-list">
<li>IntoTheBlock data shows Bitcoin and Ethereum large transaction volume increasing by 9% and 12%, respectively. Daily active addresses are up by 12% and 19.6%, respectively.</li>
<li>Coinglass data shows 76,197 traders were liquidated in the past 24 hours for $169.71 million.</li>
<li>SoSoValue data shows net inflows of $588.6 million into spot Bitcoin ETFs on Tuesday, while spot Ethereum ETFs saw net inflows of $71.2 million.</li>
</ul>
Trader Notes: Crypto trader Jelle highlighted Bitcoin's quick recovery after briefly dipping below recent lows. The reclaim of a key resistance level suggests strength, with liquidity clusters just overhead, potentially setting up for a rapid upside move..
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> took out the lows, and immediately reclaimed the key resistance level, and now pushes higher. Bunch of liquidity sitting just overhead. This could get interesting. <a href="https://t.co/Gx3txfZmjB">pic.twitter.com/Gx3txfZmjB</a>
&mdash; Jelle (@CryptoJelleNL) <a href="https://twitter.com/CryptoJelleNL/status/1937803616263229705?ref_src=twsrc%5Etfw">June 25, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
On the other hand, Rekt Capital <a href="https://x.com/rektcapital/status/1937826121334309111">noted</a> Bitcoin is now positioned to break out of its multi-week downtrend. But to confirm a reversal, Bitcoin must close the week solidly above a key diagonal trendline, not just wick above it.
Ted Pillows <a href="https://x.com/TedPillows/status/1937816790354329876">pointed</a> out that Ethereum is currently holding the range low but must reclaim $2,525 to resume upward momentum toward the range highs.
Ameba <a href="https://x.com/Ameba_NM/status/1937768205960802625">observed</a> that Solana's reclaim of the MH level could lead to a short-term surge toward the monthly open. A breakout above that would likely bring strong bullish momentum.
Trader Tardigrade <a href="https://x.com/TATrader_Alan/status/1937798438407835893">emphasized</a> that Dogecoin continues to respect a long-term weekly support trendline that&#8217;s held for over 18 months, suggesting the meme coin remains technically sound.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46080751/anthony-pomplianos-procap-buys-over-3700-bitcoin-whats-driving-the-aggressive-bet">Anthony Pompliano&#8217;s ProCap Buys Over 3,700 Bitcoin—What&#8217;s Driving The Aggressive Bet?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Hold Gains As Crypto ETF Inflows Continue

Sonder Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOND#NASDAQ">SOND</a>) ("Sonder" or the "Company") today announced that after a transformative tenure as Co-Founder and Chief Executive Officer, Francis Davidson has stepped down as Sonder's Chief Executive Officer and as a member of the Company's Board of Directors. Janice Sears, Sonder's Chairperson of the Board, has been appointed Interim Chief Executive Officer, effective immediately. Ms. Sears will continue to serve as Sonder's Board Chairperson. The Board intends to immediately initiate a search process to identify Sonder's next CEO.
 &nbsp;

Management

SOND

Sonder Holdings CEO Francis Davidson Steps Down; Board Chair Janice Sears Named Interim CEO, Effective Immediately

<ul>
<li>Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)</li>
<li>Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersen</li>
<li>Based on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to registrational stage studies, building on extensive experience in SMA &nbsp;</li>
</ul>
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=mqiGWYMuKfEonBYy6qMH-_1QrPITPn3OfJOt0ipADJSKUxY8-i9HvsJlmdCbsNsl39Ta1psj5YPS_0RxQ_acvg==">Biogen</a> Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) announced topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense oligonucleotide (ASO) being developed for the treatment&nbsp;of spinal muscular atrophy (SMA). Leveraging the same mechanism of action as SPINRAZA (nusinersen) but designed to achieve greater potency, salanersen has the potential to achieve high efficacy and enable once yearly dosing. An interim analysis of the Phase 1 study in participants with SMA who were previously treated with gene therapy was conducted to inform the decision on whether to move salanersen forward into registrational studies. Both dose levels tested, 40 mg and 80 mg, given once a year, were generally well-tolerated and led to substantial slowing of neurodegeneration, as shown by reductions in neurofilament. Exploratory clinical outcome data shows clinically meaningful improvements in function and attainment of new World Health Organization (WHO) milestones over 1 year. These data will be presented today at the SMA Research &amp; Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif.

BIIB

Biogen Announces Topline Results From Phase 1 Study Of Salanersen, Antisense Oligonucleotide Being Developed For Treatment Of Spinal Muscular Atrophy

Reflecting the surging tide of artificial intelligence, Wedbush Securities analyst Dan Ives has raised his price target for Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) to $600, up from an earlier estimate of $425, citing a &#8220;massive adoption wave&#8221; of AI-driven Azure services.
What Happened: The announcement, made via X, underscores Ives&#8217; confidence in Microsoft's pivotal role in the AI revolution, dubbing it the company's &#8220;shining moment.&#8221;
The new target implies a 23% upside for Microsoft investors based on Tuesday's closing price.
Ives, a veteran tech bull on Wall Street, bases his bullish outlook on recent field checks revealing robust AI customer adoption.
Microsoft's Azure cloud platform, enhanced by innovations like Nvidia Corp.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) <a href="https://www.benzinga.com/markets/equities/25/05/45510847/jensen-huang-satya-nadella-tout-40x-speed-up-in-azure-powered-ai-as-microsoft-nvidia-deepen-supercomputing-alliance">Hopper GPUs and custom-built silicon</a>, is at the forefront, with monetization strategies outlined in the Azure API Management framework driving significant growth. 
The new target, approximately 25% premium over the current Wall Street consensus of $517.85, reflects Ives' belief that AI infrastructure is propelling Microsoft ahead of competitors.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Raising our price target on Microsoft to $600 reflecting incrementally bullish recent AI customer checks in the field with a massive adoption wave of AI driven Azure monetization now on the doorstep for MSFT. We strongly view this as Microsoft&#39;s &quot;shining moment&quot; with AI &#x1f3c6;&#x1f402;&#x1f525;&#x1f37f;
&mdash; Dan Ives (@DivesTech) <a href="https://twitter.com/DivesTech/status/1937820305348837882?ref_src=twsrc%5Etfw">June 25, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/equities/25/06/46068345/blackrock-bets-big-on-defense-companies-amid-escalating-geopolitical-tensions-palantir-lockheed-martin-northrop-grumman-among-stocks-in-focus">BlackRock Bets Big On Defense Companies Amid Escalating Geopolitical Tensions: Palantir, Lockheed Martin, Northrop Grumman Among Stocks In Focus</a>
Why It Matters: Currently, based on the <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">29 analysts tracked by Benzinga</a>, MSFT has a consensus target price of $517.85 apiece, with a &#8216;buy&#8217; rating.
The targets range from $475 to $605. Recent price targets from Wells Fargo, Citigroup, and RBC Capital imply a 15.07% upside for Microsoft Corp.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="385" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25065238/MSFT-ANR-new-1024x385.png" alt="" class="wp-image-961398" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25065238/MSFT-ANR-new-1024x385.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25065238/MSFT-ANR-new-300x113.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25065238/MSFT-ANR-new-768x289.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25065238/MSFT-ANR-new.png 1072w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
MSFT shares were up 0.22% in premarket on Wednesday and ended 0.85% higher at $490.11 apiece on Tuesday. It has risen by 17.09% on a year-to-date basis and 8.68% over the past year. 
Benzinga Edge Stock Rankings shows that MSFT had a stronger price trend over the short, medium, and long term. Its momentum ranking was solid; however, its value ranking was poor at the 13.32nd percentile. The details of other metrics are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="865" height="130" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25065151/MSFT-EDGE.png" alt="" class="wp-image-961395" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25065151/MSFT-EDGE.png 865w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25065151/MSFT-EDGE-300x45.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25065151/MSFT-EDGE-768x115.png 768w" sizes="(max-width: 865px) 100vw, 865px" /></a></figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Wednesday. The SPY was down 0.054% at $607.11, while the QQQ rose 0.16% to $540.66, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/25/06/46089173/michael-saylor-offers-btc-credit-model-as-bill-pulte-pushes-crypto-for-fannie-mae-freddie-mac-could-bitcoin-soon-count-toward-mortgage-qualification">Michael Saylor Offers BTC Credit Model As Bill Pulte Pushes Crypto For Fannie Mae, Freddie Mac: Could Bitcoin Soon Count Toward Mortgage Qualification?</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. 
Image via Shutterstock

MSFT

NVDA

Microsoft Stock Poised For 23% Rally As AI Monetization Gains Steam, Dan Ives Says

- End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer's Disease Scheduled -
- Applications for IND and Breakthrough Status Filed for Dementia with Lewy Bodies -
PURCHASE, N.Y., June 25, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=KdsnSg5rcq4bA2J8hqBpQj8lWM9rgYhvZSWM125zklYwbZm_6JoBEOJUD2FOniY56qp67Xy19gTIn6KYIWxAyCPRQS_5gV-sW1-hmlNjqL5TQaXxGCUOix93YEGeGae5">Cognition Therapeutics, Inc.</a>, (the Company or Cognition) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the company will conduct an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) on July 9, 2025. During the meeting, the Cognition team will review results of the Phase 2 'SHINE' study (<a href="https://www.globenewswire.com/Tracker?data=_MCpzuFFyrefjxZ9d-cZnmAO1MOxvxFHE4LkQnqVInCbPk2FtdhDRQ5HLjtXhUEv7g3xWF6na98ny1Z2eS4QZjXxm1kNgasp2Ix5JVSe0HyImfx1ext1iotjp9v-KO46">NCT03507790</a>) of zervimesine (CT1812) in mild-to-moderate Alzheimer's disease. In addition, proposed plans for a Phase 3 program designed to support regulatory approval of zervimesine in this patient population will be discussed with the FDA.
Breakthrough therapy designation is designed by the FDA to expedite the development and regulatory review of promising therapies for serious or life-threatening conditions where preliminary clinical evidence suggests substantial improvement over existing treatments. The designation facilitates more intensive FDA guidance, cross-disciplinary collaboration, and eligibility for rolling submission and priority review. The FDA typically reviews applications for breakthrough designation within 60 days.
The expanded access program (EAP) for zervimesine in DLB is progressing with high interest among former SHIMMER participants. The EAP is enrolling adults with DLB who participated in the SHIMMER study, as well as others who meet the program's eligibility criteria. While one site is currently open, the Cognition team is working closely with other sites to complete onboarding so that they may be open to patients soon.

CGTX

Cognition Therapeutics To Conduct End-Of-Phase 2 Meeting With FDA For Mild-To-Moderate Alzheimer's Disease On July 9, 2025

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fionis.com%2F&amp;esheet=54281950&amp;newsitemid=20250625591486&amp;lan=en-US&amp;anchor=Ionis+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=170ceac2a025b1dbda3decf050844ab4">Ionis Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) today announced that its partner, Biogen, shared positive topline results from the Phase 1 study of salanersen (ION306/BIIB115), an investigational antisense oligonucleotide (ASO) being developed for the potential treatment of spinal muscular atrophy (SMA). Leveraging the same mechanism of action as SPINRAZA&#xAE; (nusinersen) but designed to achieve greater potency, salanersen has the potential to achieve high efficacy and enable once-yearly dosing. Both dose levels tested, 40 mg and 80 mg, given once a year, were generally well-tolerated and led to substantial slowing of neurodegeneration, as shown by reductions in neurofilament. Exploratory clinical outcome data show clinically meaningful improvements in function and attainment of new World Health Organization (WHO) milestones over one year. These data will be presented today at the SMA Research &amp; Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif.
The Phase 1 single ascending dose study was designed to evaluate the safety, tolerability and pharmacokinetics of salanersen. The trial consisted of two parts: Part A, a randomized and placebo-controlled segment in healthy adult male volunteers and Part B, an open-label segment in pediatric participants with SMA who previously received ZOLGENSMA&#xAE; (onasemnogene abeparvovec) and had investigator-reported suboptimal clinical status. Interim results are from Part B (n=24) in individuals who received either 40 mg or 80 mg salanersen once a year. In participants with elevated baseline concentrations of neurofilament light chain (NfL), indicating ongoing neurodegeneration, initiation of salanersen led to mean reductions in NfL of 70% at 6-months which were sustained through the one-year dosing interval.

Comments

Susquehanna Community

Noticias

Últimas noticias sobre Susquehanna Community (OTC:SQCF) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL